Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.
Saved in:
| Title: | Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. |
|---|---|
| Authors: | Chan A; Breast Clinical Trials Unit, Breast Cancer Research Centre-WA & Curtin University, Perth, Australia. Electronic address: arlenechan@me.com., Moy B; Breast Oncology Program, Massachusetts General Hospital Cancer Center, Boston, MA., Mansi J; Oncology & Haematology Clinical Trials, Guy's and St Thomas Hospital NHS Foundation Trust and Biomedical Research Centre, King's College, London, United Kingdom., Ejlertsen B; Department of Oncology, Rigshospitalet, Copenhagen, Denmark., Holmes FA; Texas Oncology/US Oncology Research, Houston, TX., Chia S; Medical Oncology, BC Cancer Agency, Vancouver, BC, Canada., Iwata H; Clinical Oncology, Aichi Cancer Center, Chikusa-ku, Nagoya, Japan., Gnant M; Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria., Loibl S; Center for Hematology and Oncology Bethanien, Frankfurt, Germany., Barrios CH; Centro de Pesquisa em Oncologia, Hospital São Lucas, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil., Somali I; Department of Oncology, Dokuz Eylul Universitesi Tip Fakultesi Hastanesi Tibbi Onkoloji Anabilim Dali Mithatpaşa, Balçova, Izmir, Turkey., Smichkoska S; University Clinic for Radiotherapy and Oncology, Ss Cyril and Methodius University of Skopje, Skopje, Republic of Macedonia., Martinez N; Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain., Alonso MG; Oncología Médica, Hospital Universitario Nuestra Señora de la Candelaria Ctra. Del Rosario, Sta. Cruz De Tenerife, Canarias., Link JS; Breastlink Medical Group, Inc, Santa Ana, CA., Mayer IA; Division of Hematology/Oncology, Breast Cancer Program, Vanderbilt-Ingram Cancer Center, Nashville, TN., Cold S; Onkologisk Afdeling R, Odense University Hospital, Odense, Denmark., Murillo SM; Hospital Universitario Arnau Vilanova Servei d'Oncologia Mèdica i Hematologia, Lleida, Spain., Senecal F; Physician Medical Center, Northwest Medical Specialties PLLC, Tacoma, WA., Inoue K; Breast Oncology, Saitama Cancer Center, Kita-Adachi, Japan., Ruiz-Borrego M; Oncología, Hospital Universitario Virgen del Rocio, Seville, Spain., Hui R; Crown Princess Mary Cancer Centre, Westmead Hospital and University of Sydney, Sydney, NSW, Australia., Denduluri N; Virginia Cancer Specialists, Arlington, VA., Patt D; Texas Oncology - Round Rock, Austin, TX., Rugo HS; Department of Medicine (Hematology/Oncology), University of California San Francisco Comprehensive Cancer Center, San Francisco, CA., Johnston SRD; The Breast Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom., Bryce R; Puma Biotechnology Inc., Los Angeles, CA., Zhang B; Puma Biotechnology Inc., Los Angeles, CA., Xu F; Puma Biotechnology Inc., Los Angeles, CA., Wong A; Puma Biotechnology Inc., Los Angeles, CA., Martin M; Medical Oncology Service, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Madrid, Spain. |
| Corporate Authors: | ExteNET Study Group |
| Source: | Clinical breast cancer [Clin Breast Cancer] 2021 Feb; Vol. 21 (1), pp. 80-91.e7. Date of Electronic Publication: 2020 Oct 06. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 100898731 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0666 (Electronic) Linking ISSN: 15268209 NLM ISO Abbreviation: Clin Breast Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
